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Human paraoxonase 1 (PON1) has been portrayed as a catalytic bioscavenger which can hydrolyze large
amounts of chemical warfare nerve agents (CWNAs) and organophosphate (OP) pesticides compared to
the stoichiometric bioscavengers such as butyrylcholinesterase. We evaluated the protective efﬁcacy of
puriﬁed human and rabbit serum PON1 against nerve agents sarin and soman in guinea pigs. Catalytically
active PON1 puriﬁed from human and rabbit serum was intravenously injected to guinea pigs, which
were 30 min later exposed to 1.2  LCt50 sarin or soman using a microinstillation inhalation exposure
technology. Pre-treatment with 5 units of puriﬁed human and rabbit serum PON1 showed mild to
moderate increase in the activity of blood PON1, but signiﬁcantly increased the survival rate with
reduced symptoms of CWNA exposure. Although PON1 is expected to be catalytic, sarin and soman
exposure resulted in a signiﬁcant reduction in blood PON1 activity. However, the blood levels of PON1 in
pre-treated animals after exposure to nerve agent were higher than that of untreated control animals.
The activity of blood acetylcholinesterase and butyrylcholinesterase and brain acetylcholinesterase was
signiﬁcantly higher in PON1 pre-treated animals and were highly correlated with the survival rate. Blood
O2 saturation, pulse rate and respiratory dynamics were normalized in animals treated with PON1
compared to controls. These results demonstrate that puriﬁed human and rabbit serum PON1
signiﬁcantly protect against sarin and soman exposure in guinea pigs and support the development of
PON1 as a catalytic bioscavenger for protection against lethal exposure to CWNAs.
Published by Elsevier Inc.
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1. Introduction
Chemical warfare nerve agents (CWNAs) and organophosphate
(OP) pesticides exert their biological effects mainly by the
irreversible inhibition of acetylcholinesterase (AChE), an enzyme
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involved in the catabolism of neurotransmitter acetylcholine (ACh)
[1–3]. The inhibition of AChE results in accumulation of ACh in the
peripheral and central nervous system leading to acute cholinergic
crisis. The existing pretreatments against CWNA toxicity are
centered on the development of reversible cholinesterase inhibiting compounds such as pyridostigmine bromide [4]. Post-exposure
treatments include AChE re-activator 2-pralidoxime, anti-cholinergic drug atropine sulfate and anticonvulsant diazepam [5–7]. But
current treatments do not completely protect against CWNA
induced neuropathology and behavioral deﬁcits.
Prophylactic pre-treatment with bioscavenger enzymes such as
human butyrylcholinesterase (BChE) has emerged as a promising
strategy for protection against lethal doses of CWNA exposure [8–
10]. BChE is able to scavenge the toxic CWNA and OP in the blood
before they reach the target organs. The stoichiometric 1:1 binding
of BChE and nerve agent diminishes its protective efﬁcacy with
lower doses of the enzyme. Researchers worldwide are now more
focused on the discovery and development of catalytic bioscavenger enzymes, which are expected to hydrolyze large amounts of
CWNAs and OPs without the loss of activity. Development of
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catalytic bioscavenger will reduce the amount of puriﬁed enzyme
required for treatment, and lesser demands on future logistics and
resources for military operational medicine.
A promising catalytic bioscavenger against CWNAs and OPs is
human serum paraoxonase 1 (PON1) (EC 3.1.8.1) [11–13]. PON1 is
synthesized mainly in the liver and secreted to blood to associate
with high density lipoproteins, although mRNA analysis showed its
presence in many other tissues [14,15]. The secreted human blood
PON1 enzyme is 355 amino acids long with a molecular mass in the
range of 43–45 kDa [16,17]. On the other hand, rabbit serum PON1
is a 359 amino acid long protein with 85% identity to human serum
PON1 [18–20]. Both human and rabbit serum PON1 exhibit
multiple types of polymorphisms which affect the catalytic activity
of the enzyme [21–23].
Puriﬁed human and rabbit serum PON1 was reported to
hydrolyze various CWNAs and OPs in vitro [11–13,17]. Human
recombinant PON1 expressed in Escherichia coli and Trichoplusia ni
larvae also showed similar hydrolysis of substrates [11,24,25]. We
have recently shown that puriﬁed human and rabbit serum and
recombinant human PON1 efﬁciently hydrolyze nerve agents
tabun, sarin and soman under in vitro conditions [26]. Furthermore, we demonstrated that the CWNA hydrolysis activity in the
puriﬁed enzyme is intrinsic to PON1 activity and PON1 acts as a
catalytic bioscavenger.
Evaluation of the in vivo efﬁcacy of puriﬁed PON1 pre- or postexposure treatment in mice showed signiﬁcant protection against
chlorpyrifos oxon (CPO) [27]. Further investigations using PON1
knock-out mice showed dramatic increase in the sensitivity to CPO
toxicity [28]. Endogenous expression of PON1 in mice using
adenovirus vector or naked PON1 DNA administration also showed
signiﬁcant expression and protection against chlorpyrifos, diazoxon and soman induced toxicity [29–31]. In vivo evaluation of
protective efﬁcacy of PON1 has been described in mice using other
OPs and injury models [32–35].
The objective of this study was to evaluate the protective
efﬁcacy of puriﬁed human and rabbit serum PON1 against sarin
and soman exposure in a guinea pig inhalation model. Microinstillation inhalation exposure that is well established in our
laboratory was used to endotracheally aerosolize the CWNAs
[36,37]. The technology involves aerosolization of nerve agents
using a microcatheter, which has several peripheral holes that
pump air at the tip to aerosolize the agent delivered in the central
hole. The microinstillation technology is safe, and requires
minimum amount of the agent to produce a meaningful dose
response. We demonstrate that pre-treatment with puriﬁed PON1
protects against nerve agent exposure.
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obtained from Pﬁzer Pharmaceuticals (New York, NY). Chemical
warfare nerve agents sarin and soman were obtained from US
Army Medical Research Institute of Chemical Defense (USAMRICD), Aberdeen Proving Ground, MD.
2.2. Animals
All animal research was conducted in compliance with the
Animal Welfare Act and other federal statutes and regulations
relating to animals and experiments involving animals and
adhered to principles stated in the Guide for the Care and Use
of Laboratory Animals (NRC Publication 1996 edition). All animal
procedures were performed at USAMRICD with an IACUC approved
protocol. Male Hartley guinea pigs (250–300 g) from Charles River
Laboratories (Wilmington, MA) were used in this study.
2.3. Puriﬁcation of human and rabbit serum PON1
Large amount of PON1 was puriﬁed from human and rabbit
serum as described earlier using multiple chromatographies with
modiﬁcations [38,39]. A brief methodology of the PON1 puriﬁcation was described recently [26]. The purity of human and rabbit
serum PON1 was conﬁrmed by SDS-PAGE and immunoblotting.
The catalytic activity of highly puriﬁed PON1 preparations (>95%
pure) was analyzed by using p-NPA or phenyl acetate as substrates.
Enzyme activity in units was calculated from the initial linear rates
of hydrolysis of substrates (p-NPA or phenyl acetate) using molar
extinction coefﬁcients of p-nitrophenol (18 mM1 cm1 at
405 nm) or phenol (1.31 mM1 cm1 at 270 nm), respectively.
2.4. Microinstillation inhalation exposure
Guinea pigs were quarantined for 1 week prior to inhalation
exposure to sarin and soman. Microinstillation inhalation exposure
was performed in these animals as described earlier [36,37]. Brieﬂy,
guinea pigs were anesthetized using a combination of telazol
(40 mg/kg, im) and medetomidine (0.125 mg/kg, sc) and intubated
with a translucent polystyrene tube. The microinstillation catheter
(Trudell Medical International, Canada) passed through the intubation tube and placed 2 cm above the bifurcation of the trachea. Sarin
and soman diluted in saline was aerosolized with a pulse rate of 40
pulses/min for 2–4 min. The animals were exposed to a ﬁnal
concentration of 846 mg/m3 of sarin or 841 mg/m3 of soman
(1.2  LCt50) [40,41]. Terminally ill animals were euthanized and
biological samples were collected. The surviving animals were
allowed to recover for 24 h and euthanized by exsanguination and
blood and tissues were collected for biochemical analysis.

2. Materials and methods
2.5. Administration of puriﬁed human and rabbit serum PON1
2.1. Materials
Phenylacetate, p-nitrophenylacetate (p-NPA), acetylthiocholine, butyrylthiocholine, tetra monoisopropyl pyrophosphortetramide (iso-OMPA), huperzine A, dithionitrobenzoic acid (DTNB),
4,40 -dipyridyl disulﬁde, 4,40 -dithiodipyridine (DTP), heparin, and
PON1 polyclonal antibody were purchased from Sigma (St. Louis,
MO). Tissue protein extraction reagent and BCA assay kit for
protein estimation were purchased from Pierce (Rockford, IL).
Microplates (96-well) were purchased from BD Biosciences (San
Jose, CA). SDS-PAGE running and transfer buffer, 4–20% Tris–
glycine gradient gel, and protein molecular weight marker was
purchased from Invitrogen (Carlsbad, CA). Immobilon polyvinylidene diﬂuoride membrane was purchased from Millipore (Billerica, MA). Enhanced chemiluminescence reagent was purchased
from GE Healthcare (Piscataway, NJ). Telazol was purchased from
Wyeth Pharmaceuticals (Madison, NJ). Meditomidine was

Animals were randomly divided into three groups – 1, control; 2,
human serum PON1 treated; and 3, rabbit serum PON1 treated. Prior
to the experiment, ear blood (20–50 ml) was collected from all the
animals into heparinized tubes. Puriﬁed human (1 mg protein) or
rabbit (0.5 mg protein) serum PON1 (50–200 ml) was administered intravenously to the experimental group of animals through
saphenous vein (5 units of enzyme per animal). After 30 min, ear
blood was again collected from these animals. Animals were
exposed to sarin or soman by using the microinstillation method as
described above. At the end of the experiment or at 24 h, cardiac
blood was collected into heparinized tubes followed by necropsy.
2.6. Measurement of pulse rate and blood O2 saturation
Blood O2 saturation and pulse rate were recorded using a pulse
oximeter (Nonin Medical Instruments, Minneapolis, MN) in
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animals exposed to sarin or soman as well as PON1 pre-treated
animals exposed to nerve agents. Pulse rate was recorded as beats
per min (bpm) and blood oxygen as % saturation of peripheral
oxygen (SpO2). The data were recorded at pre-intubation, postintubation, and 30 s intervals during and after exposure of nerve
agents for 15 min. The average values (mean  SEM) were plotted
by using GraphPad Prism software.
2.7. Blood PON1 activity assay
Ear blood and cardiac blood were diluted ﬁve times with deionized water. Aliquots of diluted blood samples were incubated
with 10 mM phenylacetate in 100 mM Tris–HCl buffer, pH 8.0
containing 2 mM CaCl2. The release of phenol was measured at
270 nm for 5 min in a kinetic mode using Spectramax M5
Spectrophotometer (Molecular Devices, Sunnyvale, CA).
2.8. AChE and BChE activity assay
Different parts of brain (frontal cortex, hind cortex, cerebellum,
mid brain and hippocampus) were homogenized with 1:7 tissue
protein extraction reagent (25 mM bicine, 150 mM NaCl, pH 7.6
containing mild detergent like 0.1% TX-100) at 4 8C using a tissue
homogenizer and clariﬁed by centrifugation. Aliquots of diluted
blood or tissue samples were pre-incubated with 4 mM of isoOMPA for 30 min at room temperature to inhibit the associated
BChE activity. AChE activity was measured by using modiﬁed
Ellman assay with 1 mM of acetylthiocholine substrate and
0.2 mM DTP as chromogen [42–44]. For BChE activity assay, blood
or tissue samples were pre-incubated with 400 nM of huperzine A
for 30 min, followed by modiﬁed Ellman assay with 1 mM of
butyrylthiocholine as substrate and 0.2 mM DTP as the chromogen
[42–44]. The change in activity was measured at 412 nm for 5 min
in a kinetic mode using a SpectraMax M5 spectrophotometer.
Total protein levels in diluted whole blood and brain tissue
extracts were determined by BCA protein assay kit. The activity of
enzymes in whole blood and brain extracts was expressed as units/
mg protein.
2.9. Respiratory dynamics
Barometric whole body plethysmography (Buxco Electronics,
Inc., Sharon, CT) was used to measure respiratory dynamics in
conscious, unrestrained guinea pigs as described previously [45–
47]. The baseline respiratory parameters were recorded in guinea
pigs before exposure and at 4 and 24 h recovery periods after
exposure to sarin in PON1 pre-treated animals and the data were
analyzed by using BioSystem XE software.
2.10. Data analysis
Statistical analysis was performed by using GraphPad Prism
software. For the animal survival data, Fisher’s exact test was
employed. The respiratory dynamics and blood and tissue data
were analyzed by using Mann–Whitney test. Probability (p) values
less than or equal to 0.05 considered as signiﬁcant.
3. Results
3.1. Protective efﬁcacy of puriﬁed human and rabbit serum PON1
against sarin
Prophylaxis treatment with puriﬁed human and rabbit serum
PON1 showed signiﬁcant protection against sarin inhalation
exposure in guinea pigs (Table 1). 86% of the animals exposed
to 846 mg/m3 of sarin by microinstillation inhalation exposure

Table 1
Survival data of guinea pigs exposed to sarin and soman.
Groups

Total number
of animals

Sarin (846 mg/m3)
Control
14
HPON1
6
RPON1
11
Soman (841 mg/m3)
Control
10
HPON1
8
RPON1
7

Surviveda

% Survival

2
4
8

14%
67%
73%

0.03*
0.005*

2
6
5

20%
75%
71%

0.05*
0.05*

Signiﬁcanceô
(p value)

a

The number of animals survived for 24 h.
The statistical signiﬁcance of guinea pigs survival was calculated using Fisher’s
exact test. p values 0.05 is considered as signiﬁcant.
*
Statistically signiﬁcant.
ô

died within 15 min. Animals pre-treated with 5 units of puriﬁed
human serum PON1 and exposed to sarin 30 min later showed 67%
survival rate at 24 h. Fisher’s exact test analysis of survival rate
showed statistically signiﬁcant change (p = 0.03) in the human
serum PON1 pre-treated animals compared to control sarin
exposed animals (Table 1). When rabbit serum PON1 (5 units)
was used for the prophylactic treatment, guinea pigs showed 73%
survival rate at 24 h, which was also statistically signiﬁcant
(p = 0.005). Control animals exposed to sarin died within 15 min,
whereas animals pre-treated with PON1 either survived for 24 h or
died 2–6 h after sarin exposure. PON1 pre-treated animals
survived for 24 h were active and healthy with minimum signs
of toxicity from sarin exposure.
3.2. Puriﬁed human and rabbit serum PON1 protects against soman
exposure
Animals exposed to 841 mg/m3 of soman showed 20% survival
rate; most of the animals died within 10–15 min after agent
exposure (Table 1). Prophylaxis with human serum PON1 showed
75% survival rate in guinea pigs exposed to soman, with a statistical
signiﬁcance of p = 0.05, compared to soman controls. In the case of
rabbit serum PON1, the survival rate after soman exposure was
found to be 71%; Fisher’s exact test showed a statistical
signiﬁcance of p = 0.05. Thus, both puriﬁed human and rabbit
serum PON1 showed similar levels of protection against soman
exposure. In both PON1 treated groups, animals survived for 24 h
or died 4–8 h after soman exposure.
3.3. PON1 prophylaxis normalizes pulse rate and blood O2 saturation
in sarin and soman exposed guinea pigs
Guinea pigs exposed to sarin showed a gradual drop in the heart
rate; 40% drop was observed in the ﬁrst 10 min followed by 70%
drop by 15 min, before death of the animal (Fig. 1A). Puriﬁed
human and rabbit serum PON1 pre-treated animals exposed to
sarin also showed a gradual decrease in the pulse rate at the initial
stages of the experiment up to 5 min, and then increased
signiﬁcantly and maintained normal pulse rate until the end of the
experiment (Fig. 1A and B). When the guinea pigs were exposed to
soman, there was an immediate and signiﬁcant drop of pulse rate
in the ﬁrst 5 min, followed by a gradual increase up to 10 min and
then a gradual decrease to less than 60% of normal value leading to
death of the animal (Fig. 1C). Animals pre-treated with human
serum PON1 and exposed to soman showed a relatively less
decrease in the pulse rate at the beginning of the experiment and
maintained the normal value during the course of the experiment
(Fig. 1C). In the case of rabbit serum PON1 pre-treated animals
exposed to soman, there was an immediate drop in the pulse rate
till 5 min, followed by a signiﬁcant increase to normal value by
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Fig. 1. Pulse rate of animals exposed to sarin and soman. Male Hartley guinea pigs were administered either with saline or 5 units of puriﬁed human or rabbit serum PON1
through saphenous vein. After 30 min, the animals were exposed to 846 mg/m3 of sarin (A and B) or 841 mg/m3 of soman (C and D) using microinstillation method as
described in ‘‘Section 2’’. The pulse rate in beats per min (bpm) was recorded using a pulse oximeter every 30 s for 15 min. Mean  SEM values of pulse rate were plotted against
time (min) using GraphPad Prism software. Saline controls, n = 8; puriﬁed human serum PON1 (HPON1) exposed to sarin, n = 4; HPON1 exposed to soman, n = 6; puriﬁed rabbit
serum PON1 (RPON1) exposed to sarin, n = 8; and RPON1 exposed to soman, n = 5.

7.5 min and that was maintained at normal levels during the
15 min recording (Fig. 1D).
The blood O2 saturation curve of sarin exposed animals showed
a decrease within ﬁrst 5 min, that was returned to normal levels at
7.5 min and then decreased to less than 50% of normal value at 10–
15 min after exposure (Fig. 2A). In the case of animals pre-treated
with puriﬁed human and rabbit serum PON1 exposed to sarin, a
signiﬁcant drop was observed in the blood O2 saturation up to
5 min, followed by a return to normal levels that was maintained
till the end of the recording (Fig. 2A and B). Blood O2 saturation
curves of soman exposed animals showed a similar pattern to the
pulse rate, with a drop in the ﬁrst 5 min, followed by a return back
to normal levels at 10 min and then a gradual decrease to 25% of
the normal value (Fig. 2C). Human and rabbit serum PON1 pretreated animals exposed to soman also showed a drop in the O2
saturation in the ﬁrst 5 min, that was returned back to normal
levels and maintained during the 15 min recordings (Fig. 2C and D).
These data correlated with the increased survival rate observed
with human and rabbit serum PON1 treated animals after sarin and
soman exposure.
3.4. PON1 treatment reverses respiratory functional abnormalities
after sarin exposure
Barometric whole-body plethysmography data of animals
pre-treated with puriﬁed human and rabbit serum PON1 and
exposed to sarin are shown in Figs. 3 and 4. Controls with
846 mg/m3 sarin were not included due to the mortality of these
animals, but previous data with 508 mg/m3 sarin were used for

comparison [47]. Respiratory frequency was lower at 4 h after
sarin exposure in PON1 treated animals compared to baseline
values and was normalized at 24 h (Fig. 3A). Tidal volume in
PON1 treated animals at 4 and 24 h was similar to baseline
readings (Fig. 3B). Minute ventilation that was increased at
508 mg/m3 sarin exposure in the previous study showed
normalization in PON1 treated animals (Fig. 3C). Peak inspiratory
ﬂow which showed an increase following 508 mg/m3 sarin
exposure at 4 h as reported previously was decreased and was
close to normal baseline in PON1 treated animals exposed to
846 mg/m3 sarin (Fig. 3D) [47]. Peak expiratory ﬂow that tended
to increase strongly at 4 h after exposure to 508 mg/m3 sarin
changed much less in PON1 treated animals exposed to sarin
(Fig. 3E). Time of inspiration (Ti) and time of expiration (Te) that
was increased at 24 h after 508 mg/m3 sarin exposure was
returned to normal levels in PON1 treated animals exposed to
846 mg/m3 sarin (Fig. 4A and B). At 4 h, Ti and Te was increased in
PON1 treated animals exposed to 846 mg/m3 sarin, whereas
508 mg/m3 sarin exposure resulted in a decrease [47]. End
inspiratory pause did not show any signiﬁcant change in PON1
treated animals exposed to sarin compared to the baseline values
(Fig. 4C). Meanwhile, end expiratory pause that was increased at
24 h after exposure to 508 mg/m3 sarin was normalized in PON1
administered animals exposed to 846 mg/m3 sarin (Fig. 4D). The
decrease in Penh and Pause at 508 mg/m3 sarin exposure was
returned to a normal level in PON1 treated animals exposed to
846 mg/m3 sarin at 24 h (Fig. 4E and F). At 4 h, PON1 treated
animals exposed to sarin showed increased Penh and Pause
compared to baseline values.
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Fig. 2. Blood O2 saturation curves in animals exposed to sarin and soman. As described in Fig. 1, guinea pigs were administered either with saline or 5 units of puriﬁed human
or rabbit serum PON1 and exposed to 846 mg/m3 of sarin (A and B) or 841 mg/m3 of soman (C and D). The blood O2 saturation was recorded using a pulse oximeter every 30 s
for 15 min and mean  SEM values were plotted. Saline controls, n = 8; HPON1 exposed to sarin, n = 4; HPON1 exposed to soman, n = 6; RPON1 exposed to sarin, n = 8; and RPON1
exposed to soman, n = 5.

Fig. 3. Respiratory dynamics of PON1 pre-treated guinea pigs exposed to sarin. Respiratory frequency (A), tidal volume (B), minute ventilation (C), peak inspiratory ﬂow (D)
and peak expiratory ﬂow (E) were measured in guinea pigs before sarin exposure (baseline) and at 4 and 24 h after sarin exposure (846 mg/m3) in puriﬁed human and rabbit
serum PONI (5 units) pre-treated animals as described in ‘‘Section 2’’. n = 6 for baseline, 3 for HPON1 and RPON1 (*0.05 < p < 0.01).
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Fig. 4. Reversal of respiratory dynamics in PON1 pre-treated guinea pigs exposed to sarin. As described in Fig. 3, barometric plethysmography was performed in PON1 pretreated animals. Mean  SEM values of time of inspiration (A), time of expiration (B), end inspiratory pause (C), end expiratory pause (D), Penh (E) and Pause (F) were calculated and
plotted using GraphPad Prism software. n = 6 for baseline, 3 for HPON1 and RPON1 (*0.05 < p < 0.01).

3.5. Blood PON1, AChE and BChE activity in guinea pigs treated with
PON1 and exposed to sarin
Guinea pigs exposed to 846 mg/m3 sarin showed a signiﬁcant
reduction in the activity of the PON1 in the blood (Fig. 5A). Animals
pre-treated with 5 units of human and rabbit serum PON1 showed
a signiﬁcant increase in the blood level. PON1 pre-treated animals
exposed to sarin also showed a decrease in the activity of PON1 in
the blood like sarin controls (Fig. 5A). However, the activity of
PON1 in the pre-treated animals after sarin exposure was higher
than that of sarin controls. Thus, there is a trend of higher levels of
PON1 remaining in the blood of surviving animals possibly as a
consequence of protection against sarin.
Blood AChE activity in sarin exposed animals was inhibited
about 80% as reported earlier [48]. Animals pre-treated with both
human and rabbit serum PON1 showed an increase in the activity
of blood AChE, but this increase was not signiﬁcant (Fig. 5B). After
exposure to sarin, PON1-treated animals showed a signiﬁcant
decrease in the AChE activity and the resultant AChE activity was
similar to normal levels in unexposed guinea pigs (Fig. 5B). Thus,
the surviving animals after sarin exposure in the PON1 pre-treated
group showed no signiﬁcant change in the activity of blood AChE
owing to the protective effects of PON1.
BChE activity in the blood of sarin exposed control animals
showed a signiﬁcant reduction similar to PON1 activity (Fig. 5C).
The PON1 pre-treated animals did not show any signiﬁcant
increase in BChE activity. The decrease in the activity of blood BChE
was signiﬁcantly less in PON1 administered guinea pigs compared
to sarin exposed controls (Fig. 5C). Exposure to sarin showed a
decrease in the activity of blood BChE in human PON1 pre-treated
animals, while rabbit PON1 treated animals did not show any

signiﬁcant reduction. These data demonstrate that animals pretreated with human and rabbit serum PON1 protect against CWNA
and retain the activity of BChE after nerve agent exposure.
3.6. Activity of PON1, AChE and BChE in the blood of guinea pigs
treated with PON1 and exposed to soman
Soman exposure (841 mg/m3) also signiﬁcantly reduced the
activity of blood PON1 activity in guinea pigs (Fig. 5D). Marginal
increase in the activity of the PON1 in the blood of pre-treated
animals was signiﬁcantly reduced after soman exposure. The blood
PON1 activity in human serum PON1 pre-treated animals after
soman exposure was higher than that of soman controls, while
rabbit serum PON1 pre-treated animals did not show any major
change in the activity after soman exposure compared to the
soman exposed controls (Fig. 5D).
As observed in the case of sarin exposure, 841 mg/m3 of soman
exposure also showed a signiﬁcant reduction in the activity of
blood AChE (<80% reduction) (Fig. 5E). The PON1-induced activity
of AChE was reduced after soman exposure but this decrease was
signiﬁcantly less compared to that seen in soman controls (Fig. 5E).
Relatively higher concentration of AChE in PON1 pre-treated
animals after soman exposure can be attributed to the protective
efﬁcacy of exogenous PON1 and that contributes to the increased
survival of these animals.
Analysis of blood BChE activity in soman exposed guinea pigs
showed results more or less similar to that observed with sarin
exposure. The activity of blood BChE was signiﬁcantly reduced
after soman exposure (Fig. 5F). Pre-treatment with puriﬁed PON1
did not affect the BChE activity, but caused a signiﬁcant reduction
in this activity after exposure to soman. Compared to soman
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Fig. 5. Activity of PON1, AChE and BChE in the blood of guinea pigs exposed to sarin and soman. Guinea pigs were administered with 5 units of puriﬁed human or rabbit serum
PON1. After 30 min, the animals were exposed to 846 mg/m3 of sarin (A–C) or 841 mg/m3 of soman (D–F) as described in ‘‘Section 2’’. Pre- and post-exposed blood samples
were analyzed for PON1 activity using phenylacetate as the substrate (A and D), AChE activity (B and E), and BChE activity (C and F) using modiﬁed Ellman assay in triplicate.
The results were expressed as percentage of the activity of enzymes in the blood of control animals before sarin exposure. n = 7 for control, 4–6 for HPON1, and 5–8 for RPON1
(*0.05 < p < 0.01; **0.01 < p < 0.001; ***p < 0.001).

controls, the blood BChE activity was signiﬁcantly higher in PON1
pre-treated animals after soman exposure (Fig. 5F). The data with
soman exposure resembles that of sarin, demonstrating that pretreatment with puriﬁed PON1 can result in the retention of BChE
activity.
3.7. AChE activity in different regions of brain in sarin and soman
exposed guinea pigs
AChE activity in the brain of control untreated animals and sarin
and soman exposed animals with and without PON1 administration is expressed as percentage of control unexposed animals
(Fig. 6). The observed data showed 70–90% inhibition of AChE
activity in the frontal cortex of animals exposed to sarin and soman
compared to unexposed controls (Fig. 6A). AChE activity in the
frontal cortex of PON1 treated animals exposed to sarin showed an
increase compared to unexposed controls (signiﬁcant in the case of
rabbit PON1). PON1 treated animals exposed to sarin and soman
showed signiﬁcant increase in AChE activity and the values are
near to unexposed animals compared to sarin and soman controls
(Fig. 6A). Similar levels of AChE activity were observed in the hind
cortex in PON1 treated animals exposed to sarin and soman
(Fig. 6B). AChE activity in the cerebellum of PON1 treated sarin and
soman exposed animals was signiﬁcantly higher than sarin and
soman controls (Fig. 6C). However, unlike the cortex, the AChE
activity in the cerebellum of PON1 treated animals exposed to sarin
was not higher than the unexposed controls (compare Fig. 6C with
Fig. 6A and B). Midbrain and hippocampus also showed very

similar results to that of cerebellum with AChE activity in PON1
administered sarin and soman exposed animals (Fig. 6D and E).
4. Discussion
The present study demonstrates that administration of exogenous serum puriﬁed human and rabbit PON1 signiﬁcantly protects
against lethal (1.2  LCt50) exposure of soman and sarin in guinea
pigs. The protective efﬁcacy was observed with respect to survival,
blood O2 saturation, pulse rate, respiratory dynamics and
increased levels of blood and brain cholinesterase activity.
Although, both human and rabbit serum PON1 showed protection
against the nerve agents, the efﬁcacy of rabbit serum PON1 was
albeit higher than human serum PON1 in sarin exposed animals
probably owing to the higher catalytic efﬁciency of rabbit PON1
[26,49]. Increased activity of rabbit PON1 has been described early
and it has been attributed to the presence of Lys 192 in rabbit PON1
[49]. On the other hand, soman exposed animals showed a very
similar level of protective efﬁcacy with human or rabbit serum
PON1. Preliminary studies with lower doses of PON1 did not show
effective protection against sarin and soman exposure using this
model (data not shown). Higher doses of PON1 (more than 5 units)
was not investigated in the present study.
The microinstillation inhalation exposure technology used for
sarin and soman exposure is a method that is simple, requires less
agent, and results in accurate dosing [36,37]. The LCt50 dose of
sarin and soman was taken from our previous studies which
resulted in similar percentages of mortality [40,41]. A minor
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Fig. 6. AChE activity in different regions of brain of sarin and soman exposed guinea pigs. The experiments were performed as described in Fig. 5 and ‘‘Section 2’’ with 846 mg/
m3 of sarin and 841 mg/m3 of soman and the brain samples were collected by necropsy. Different regions of brain were dissected and extracted with tissue protein extraction
reagent. AChE activity in the brain extracts from control unexposed (n = 6), sarin or soman exposed (n = 6), HPON1 (n = 4–6) and RPON1 (n = 5–8) pre-treated nerve agent
exposed animals were analyzed by modiﬁed Ellman assay in triplicate. The results were expressed as percentage of AChE activity in the brain of normal unexposed controls.
Shown are the mean  SEM values for AChE activity from frontal cortex (A), hind cortex (B), cerebellum (C), mid brain (D) and hippocampus (E). Statistical analysis was performed
by using Mann–Whitney test (*0.05 < p < 0.01; **0.01 < p < 0.001; ***p < 0.001).

change in the mortality may be due to the handling and
administration of intravascular saline to all control animals similar
to PON1 administration. Blood drawn at 30 min after PON1
administration showed an increase in the level of PON1 activity
with a large variation (20–70%). Currently it is not known that how
rapidly exogenous PON1 is cleared from the circulation of guinea
pigs. Recently it has been reported that administration of IgG–
PON1 fusion protein in Rhesus monkeys showed a rapid removal
from circulation primarily by the liver [50]. Interestingly, our
results show that the activity of AChE was increased after PON1
administration. However, puriﬁed PON1 did not show any AChE
activity suggesting that the increase in AChE activity in PON1
pretreated animals is not due to any contaminating AChE in the
puriﬁed PON1 samples. A similar increase in AChE activity was also
found in the cortex of PON1 treated animals exposed to sarin. This
might be due to the residual blood present in the cortex in nonperfused animals since other brain regions did not show any such
increase in AChE activity in PON1 treated animals exposed to sarin.
The mechanism underlying the increase in the activity of AChE
after PON1 administration is not clear. It might be due to any
possible association between these enzymes or the interaction of
PON1 with unknown targets that leads to increased AChE activity.
Association of AChE and PON1 has been reported earlier [51–53].
Paradoxically, soman exposed animals did not show such an
increase in the cortex probably due to the rapid aging of soman
coupled AChE [54,55]. Invariably, AChE activity was signiﬁcantly
higher and close to normal levels in PON1 treated animals exposed

sarin or soman indicating that administered exogenous PON1
hydrolyzes the nerve agent before it reaches the brain.
The AChE level in the blood and brain of PON1 treated guinea
pigs exposed to sarin and soman showed signiﬁcantly higher
activity compared to corresponding agent exposed animals.
Recently, we demonstrated the catalytic efﬁciency of human
and rabbit serum puriﬁed PON1 against several CWNAs, including
sarin and soman [26]. By in vitro analysis, we found that puriﬁed
human and rabbit serum PON1 could hydrolyze sarin more
efﬁciently than soman. The current in vivo protective efﬁcacy of
PON1 correlates with our published in vitro data showing that
PON1 can hydrolyze sarin better than soman.
Whole-blood BChE activity was not modulated to the extent of
AChE in PON1-treated animals with or without nerve agent
exposure. There was no trend of increased BChE activity in the
blood after PON1 administration unlike AChE. After nerve agent
exposure, the BChE level remains higher in PON1 treated animals
compared to controls, although it is not close to normal levels.
BChE level in rabbit PON1 treated animals exposed to sarin was
higher than human PON1 treated animals, but such a difference
was not observed with soman exposure.
After sarin exposure, pulse rate decreased around 5 min and
was further reduced during the 15 min recording. Both serum
puriﬁed human and rabbit PON1 protected against the reduction
and the levels were closer to baseline during the 15 min recording
indicating strong protection against the nerve agents. Soman
resulted in sharper reduction in pulse rate than sarin and that was
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reversed by treatment with PON1. The initial reduction of pulse
rate in PON1 pre-treated animals could be an acute response to the
agent exposure, but the reduction in later time points in animals
that gradually die after agent exposure was abolished by PON1 pretreatment. PON1 treatment also prevented the peak reduction of
blood O2 saturation as well as maintained the blood O2 saturation
levels throughout the 15 min recording in sarin exposed animals
unlike the gradual decrease in control animals. The decrease in
blood O2 saturation is more severe in soman exposed animals and
that was minimal in PON1 treated animals exposed to soman and
was closer to normal after 8 min when there is a sharp reduction in
control animals that eventually died. This indicates that the air–
blood barrier and O2 exchange is maintained in animals treated
with PON1 after exposure.
Respiratory physiology was also remained closer to normal in
animals treated with PON1 and exposed to sarin. We have
reported that microinstillation inhalation exposure to 508 mg/
m3 sarin results in a signiﬁcant increase in respiratory
frequency, tidal volume, minute ventilation, peak inspiratory
ﬂow and expiratory ﬂow at 4 h after exposure [47]. Both human
and rabbit serum PON1 treated animals did not show any
signiﬁcant increase in the above respiratory dynamics parameters after exposure to 846 mg/m3 sarin at 24 h, indicating that
PON1 treatment prevents the sarin induced changes in
respiratory dynamics. Pseudo-lung resistance (Penh) and Pause
that was reduced in animals exposed to 508 mg/m3 sarin at 24 h
abolished in animals treated with PON1 and exposed to 846 mg/
m3 sarin [47]. Rabbit PON1 also showed a very similar protective
efﬁcacy with regard to respiratory dynamics. These results
suggest that PON1 treatment may be protecting against any
central respiratory depression due to nerve agent exposure that
can lead to respiratory toxicity.
The observed protective efﬁcacy of puriﬁed human and rabbit
serum PON1 with an average activity of 5 units of enzyme in guinea
pigs against sarin and soman is highly promising. 5 units of puriﬁed
PON1 correspond to 0.5–1 mg of enzyme per animal (2–4 mg/
kg, i.v.), which can protect 1.2  LCt50 of nerve agents. One of the
major concerns in the prophylaxis of PON1 is the half-life of the
protein in the in vivo system. In our experiments with guinea pigs,
we could ﬁnd only a mild to moderate increase in the activity of
blood PON1 (20–70%) after administration of exogenous PON1.
However, this increase in PON1 activity was able to protect the
animals against 1.2  LCt50 doses of nerve agents. Experiment with
higher doses of PON1 enzymes and challenging with 2–5  LCt50
nerve agents is yet to be analyzed. Another alternate approach is to
induce the expression of PON1 using pharmacological and dietary
modulators of PON1, which are reported to increase the activity of
PON1 about 2–3 fold endogenously and may have longer half-life
than puriﬁed enzyme [56–59]. Recent review by Costa et al.
addresses this as an approach of great promise and to be pursued in
parallel [60]. Design and synthesis of recombinant PON1 with
higher catalytic efﬁciency against CWNAs will also aid in the
development of more efﬁcient prophylaxis with relatively lower
concentration of enzyme for adequate protection against 2–
5  LCt50 of CWNAs. Taken together, a combination therapy with
endogenous induction of PON1 followed by exogenous administration of PON1 with higher catalytic activity can be considered as
an ideal approach to overcome the existing concerns in the
therapeutic candidacy of PON1 against lethal doses of nerve agent
toxicity.
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